MARKET

INVA

INVA

Innoviva
NASDAQ
23.92
-0.27
-1.12%
After Hours: 24.18 +0.26 +1.09% 16:33 04/15 EDT
OPEN
24.17
PREV CLOSE
24.19
HIGH
24.31
LOW
23.73
VOLUME
515.38K
TURNOVER
--
52 WEEK HIGH
25.15
52 WEEK LOW
16.52
MARKET CAP
1.77B
P/E (TTM)
7.25
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INVA last week (0406-0410)?
Weekly Report · 2d ago
3 Bargain-Cheap Small Caps Worth a Second Look
NASDAQ · 6d ago
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Nuvalent (NUVL) and Innoviva (INVA)
TipRanks · 04/08 12:20
Weekly Report: what happened at INVA last week (0330-0403)?
Weekly Report · 04/06 10:31
Weekly Report: what happened at INVA last week (0323-0327)?
Weekly Report · 03/30 10:31
Armata Pharmaceuticals FY2025 net loss more than doubled to $174 million; revenue slips 5.22% to $4.9 million
Reuters · 03/25 20:07
Innoviva Announces Annual Stockholder Meeting
Reuters · 03/24 20:53
Weekly Report: what happened at INVA last week (0316-0320)?
Weekly Report · 03/23 10:27
More
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Webull offers Innoviva Inc stock information, including NASDAQ: INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.